Management of histoplasmosis

Bibliography

• WHEAT J, SAROSI G, MCKINSEY D et al.: Practice guidelines for the management of patients with histoplas-mosis. Clin. Infect. Dis. (2000) 30:688–695.
   PubMed Web of Science ®Google Scholar
• ••These guidelines synthesise the availableliterature on the treatment of histoplasmosis and give evidence-based rankings for each treatment recommendation.
   Google Scholar
• DISMUKES WE, BRADSHER RW JR, CLOUD GC et al.: Itraconazole therapy for blastomycosis and histoplasmosis. Am. J. Med. (1992) 93:489–497.
   PubMed Web of Science ®Google Scholar
• DISMUKES WE, CLOUD G, BOWLES C et al.: Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann. Intern. Med. (1985) 103:861–872.
   PubMedGoogle Scholar
• MCKINSEY DS, KAUFFMAN CA, PAPPAS PG et al.: Fluconazole therapy for histoplasmosis. Clin. Infect. Dis. (1996) 23:996–1001.
   PubMedGoogle Scholar
• DAVIS AM, PIERSON RN, LOYD JE: Mediastinal fibrosis. Sem. Respir: Infect. (2001) 16:119–130.
   PubMedGoogle Scholar
• LOYD JE, TILLMAN BE ATKINSON JB, DES PREZ RIVI: Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) (1988) 67:295–310.
   PubMedGoogle Scholar
• JOHNSON PC, WHEAT LJ, CLOUD GA et al.: Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. (2002). In Press.
   Google Scholar
• ••This is the only randomised, double-blindtreatment trial published to date that compares two different formulations of amphotericin B for the treatment of a documented systemic fungal infection and the first randomised double-blind comparative trial carried out for the treatment of histoplasmosis.
   Google Scholar
• WHEAT LJ, CLOUD G, JOHNSON PC et al.: Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob. Agents Chemother. (2001) 45:2354–2357.
   PubMed Web of Science ®Google Scholar
• WHEAT J, HAFNER R, KORZUN AH et al.: Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. (1995) 98:336–342.
   PubMed Web of Science ®Google Scholar
• WHEAT J, MAWHINNEY S, HAFNER R et al.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am. I Med. (1997) 103:223–232.
   Google Scholar
• WHEAT LJ, CONNOLLY P, HADDAD N, LE MONTE A, BRIZENDINE E, HAFNER R: Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob. Agents Chemother. (2002) 46: 248–250.
   PubMed Web of Science ®Google Scholar
• WHEAT J, HAFNER R, WULFSON M et al.: Prevention of relapse of histoplas-mosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. (1993) 118:610–616.
   PubMed Web of Science ®Google Scholar
• DUPONT B, CREWE BROWN HH, WESTERMANN K et al.: Mycoses in AIDS. Med. Mycol (2000) 38\(Suppl. 1):259–267.
   Google Scholar
• WHEAT LJ, CONNOLLY-STRINGFIELD P, BLAIR R, CONNOLLY K, GARRINGER T, KATZ BP: Histoplasmosis relapse in patients with AIDS: detection using Histoplasma capsulatum variety capsulatum antigen levels. Ann. Intern. Med. (1991) 115:936–941.
   PubMed Web of Science ®Google Scholar
• WHEAT LJ, BATTEIGER BE, SATHAPATAYAVONGS B: Histoplasma capsulatum infections of the central nervous system: a clinical review. Medicine (Baltimore) (1990) 69:244–260.
   PubMed Web of Science ®Google Scholar
• GROLL AH, GIRI N, PETRAITIS Vet al.: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system." Infect. D (2000) 182:274–282.
   Google Scholar
• BAMBERGER DM: Successful treatment of multiple cerebral histoplasmomas with itraconazole. Clin. Infect. Dis. (1999) 28:915–916.
   PubMedGoogle Scholar
• TIRABOSCHI I, CASAS PARERA I, PIKIELNY R, SCATTINI G, MICHELI F: Chronic Histoplasma capsulatum infection of the central nervous system successfully treated with fluconazole. Ear: Neurol (1992) 32:70–73.
   PubMedGoogle Scholar
• ZHOU H, GOLDMAN M, WU J et al: Apharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection.' Clin Pharmacol (1998) 38:593–602.
   Google Scholar
• KAUFFMAN CA, CARVER PL: Use of azoles for systemic antifungal therapy. Adv. Pharmacol (1997) 39:143–89.
   PubMedGoogle Scholar
• •Extensive review of the side effects and drug-drug interactions of azoles.
   Google Scholar
• AHMAD SR, SINGER SJ, LEISSA BG: Congestive heart failure associated with itraconazole. Lancet (2001) 357:1766–1767.
   PubMed Web of Science ®Google Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N Engl. J. Med. (1994) 330:263–272.
   PubMed Web of Science ®Google Scholar
• GOODWIN SD, CLEARY JD, WALAWANDER CA et al.: Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin. Infect. Dis. (1995) 20:755–761.
   PubMed Web of Science ®Google Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and twd-Clin. Infect. Dis. (1998) 27:603–618.
   Google Scholar
• •Excellent review of the differences among the lipid preparations of amphotericin B.
   Google Scholar
• UCHIDA K, YOKOTA N, YAMAGUCHI H: In vitro activity of posaconazole against various pathogenic fungi. Inter. J. Antimicrob. Agents (2001) 18:167–172.
   PubMed Web of Science ®Google Scholar
• LI R-K, CIBLAK MA, NORDOFF N, PASARELL L, WARNOCK DW, McGINNIS MR: In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother (2000) 44:1734–1736.
   PubMedGoogle Scholar
• McGINNIS MR, PASARELL L, SUTTON DA, FOTHERGILL AW, COOPER CR JR, RINALDI MG: In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. (1997) 41:1832–1834.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, MARTINEZ M, CALDERON L, STEVENS DA: Efficacy of ravuconazole in treatment of murine histoplasmosis. Antimicrob. Agents Chemother. (2002) 46:922–924.
   PubMed Web of Science ®Google Scholar
• CONNOLLY P, WHEAT J, SCHNIZLEIN-BICK C et al.: Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. (1999) 43:322–328.
   PubMed Web of Science ®Google Scholar
• CONNOLLY P, WHEAT LJ, SCHNIZLEIN-BICK C et al.: Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immuno-compromised mice. Antimicrob. Agents Chemother. (2000) 44:2604–2608.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of M vitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. " Clin. Microbiol (1998) 36:2950–2956.
   Google Scholar
• KOHLER S, WHEAT LJ, CONNOLLY P et al.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. (2000) 44:1850–1854.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR UK, MONTALBO AM, BARCHIESI FJ, LUTHER ME RINALDI MG: Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. (1998) 42:151–153.
   PubMed Web of Science ®Google Scholar